Register for our free email digests:
Fortress Biotech Inc.
http://www.fortressbiotech.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fortress Biotech Inc.
Sentynl Signs Deal With Fortress’ Cyprium For ‘De-Risked’ Rare Disease Drug
Deal Snapshot: Sentynl will pay $20m in upfront and regulatory milestone payments through FDA approval, while Cyprium will retain 100% ownership of the priority review voucher.
Scrip Asks…What Does 2021 Hold For Biopharma? Part 5: Business Environment And Strategy
A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.
Finance Watch: One Small Pain Drug Maker And Three Biotech SPACs Launch IPOs
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
Tech Transfer Roundup: Inside The Law That Transformed The Research Landscape
The Bayh-Dole act of 1980 facilitated deal-making between private-sector firms and research institutions, largely seeding the US biotech industry. Plus, an overview of the latest tech transfer deals.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Aevitas Therapeutics, Inc.
- Altamira Bio
- Avenue Therapeutics, Inc. (ATXI)
- Baergic Bio, Inc.
- Caelum Biosciences Inc.
- Cellvation, Inc.
- Checkpoint Therapeutics, Inc.
- Coronado Biosciences, Inc. (CNDO)
- Cyprium Therapeutics, Inc.
- DiaVax Biosciences
- Helocyte, Inc.
- Journey Medical Corporation (JMC)
- Mustang Bio, Inc.
- Mustang Therapeutics, Inc. (MBIO)
- National Holdings Corporation
- Oncogenuity, Inc.
- Tamid Bio, Inc.